Table 2.
BRCA1/2 with overt carcinoma |
BRCA1/2 RRSO with occult neoplasia |
BRCA1/2 RRSO with negative pathology |
Controls | |||||
---|---|---|---|---|---|---|---|---|
Case type | BRCA1 | BRCA2 | BRCA1 | BRCA2 | BRCA1 | BRCA2 | Benign | Negative genetic testing |
Cases with p53 foci |
9/23 (39.1%) |
5/8 (62.5%) |
4/7 (57.1%) |
1/2 (50.0%) |
20/49 (40.8%) |
11/31 (35.5%) |
16/61 (26.2%) |
7/26 (26.9%) |
Mean #p53 foci/tubal segs/case* (combined) |
0.102 | 0.231 | 0.135 | 0.115 | 0.065 | 0.062 | 0.042 | 0.059 |
0.135 | 0.130 | 0.064 | 0.054 | |||||
0.134 | ||||||||
0.087 |
BRCA1/2 mutation carriers had a significantly higher frequency of p53 foci than controls (p=0.02).